Jack Mills

Dr. Jack Mills

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
TATamara Aleksic
Tamara Aleksic
NGNicki Gray
Nicki Gray
XWXiaoning Wu
Xiaoning Wu
GRGuillaume Rieunier
Guillaume Rieunier
EOEliot Osher
Eliot Osher
VMValentine Macaulay
Valentine Macaulay
Internalization of ligand-activated type I IGF receptor (IGF1R) is followed by recycling to the plasma membrane, degradation or nuclear translocation. Nuclear IGF1R reportedly associates with clinical response to IGF1R inhibitory drugs, yet its role in the nucleus is poorly characterized. Here, we investigated the significance of nuclear IGF1R in clinical cancers and cell line models. In prostate cancers, IGF1R was predominantly membrane localized in benign glands, while malignant epithelium contained prominent internalized (nuclear/cytoplasmic) IGF1R, and nuclear IGF1R associated significantly with advanced tumor stage. Using ChIP-seq to assess global chromatin occupancy, we identified IGF1R–binding sites at or near transcription start sites of genes including JUN and FAM21, most sites coinciding with occupancy by RNA polymerase II (RNAPol2) and histone marks of active enhancers/promoters. IGF1R was inducibly recruited to chromatin, directly binding DNA and interacting with RNAPol2 to upregulate expression of JUN and FAM21, shown to mediate tumor cell survival and IGF-induced migration. IGF1 also enriched RNAPol2 on promoters containing IGF1R–binding sites. These functions were inhibited by IGF1/II–neutralizing antibody xentuzumab (BI 836845), or by blocking receptor internalization. We detected IGF1R on JUN and FAM21 promoters in fresh prostate cancers that contained abundant nuclear IGF1R, with evidence of correlation between nuclear IGF1R content and JUN expression in malignant prostatic epithelium. Taken together, these data reveal previously unrecognized molecular mechanisms through which IGFs promote tumorigenesis, with implications for therapeutic evaluation of anti-IGF drugs. Significance: These findings reveal a noncanonical nuclear role for IGF1R in tumorigenesis, with implications for therapeutic evaluation of IGF inhibitory drugs. Cancer Res; 78(13); 3497–509. ©2018 AACR.

28 January 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
GRGuillaume Rieunier
Guillaume Rieunier
XWXiaoning Wu
Xiaoning Wu
LHLetitia E. Harris
Letitia E. Harris
JMJack Mills
Jack Mills
ANAshwin Nandakumar
Ashwin Nandakumar
VMValentine Macaulay
Valentine Macaulay
Inhibition of IGF receptor (IGF1R) delays repair of radiation-induced DNA double-strand breaks (DSB), prompting us to investigate whether IGF1R influences endogenous DNA damage. Here we demonstrate that IGF1R inhibition generates endogenous DNA lesions protected by 53BP1 bodies, indicating under-replicated DNA. In cancer cells, inhibition or depletion of IGF1R delayed replication fork progression accompanied by activation of ATR–CHK1 signaling and the intra-S-phase checkpoint. This phenotype reflected unanticipated regulation of global replication by IGF1 mediated via AKT, MEK/ERK, and JUN to influence expression of ribonucleotide reductase (RNR) subunit RRM2. Consequently, inhibition or depletion of IGF1R downregulated RRM2, compromising RNR function and perturbing dNTP supply. The resulting delay in fork progression and hallmarks of replication stress were rescued by RRM2 overexpression, confirming RRM2 as the critical factor through which IGF1 regulates replication. Suspecting existence of a backup pathway protecting from toxic sequelae of replication stress, targeted compound screens in breast cancer cells identified synergy between IGF inhibition and ATM loss. Reciprocal screens of ATM-proficient/deficient fibroblasts identified an IGF1R inhibitor as the top hit. IGF inhibition selectively compromised growth of ATM-null cells and spheroids and caused regression of ATM-null xenografts. This synthetic-lethal effect reflected conversion of single-stranded lesions in IGF-inhibited cells into toxic DSBs upon ATM inhibition. Overall, these data implicate IGF1R in alleviating replication stress, and the reciprocal IGF:ATM codependence we identify provides an approach to exploit this effect in ATM-deficient cancers. Significance: This study identifies regulation of ribonucleotide reductase function and dNTP supply by IGFs and demonstrates that IGF axis blockade induces replication stress and reciprocal codependence on ATM.

31 March 2023
Verified
Other
Open access
GRGuillaume Rieunier
Guillaume Rieunier
XWXiaoning Wu
Xiaoning Wu
LHLetitia E. Harris
Letitia E. Harris
JMJack Mills
Jack Mills
ANAshwin Nandakumar
Ashwin Nandakumar
VMValentine M. Macaulay
Valentine M. Macaulay
Inhibition of IGF receptor (IGF1R) delays repair of radiation-induced DNA double-strand breaks (DSB), prompting us to investigate whether IGF1R influences endogenous DNA damage. Here we demonstrate that IGF1R inhibition generates endogenous DNA lesions protected by 53BP1 bodies, indicating under-replicated DNA. In cancer cells, inhibition or depletion of IGF1R delayed replication fork progression accompanied by activation of ATR–CHK1 signaling and the intra-S-phase checkpoint. This phenotype reflected unanticipated regulation of global replication by IGF1 mediated via AKT, MEK/ERK, and JUN to influence expression of ribonucleotide reductase (RNR) subunit RRM2. Consequently, inhibition or depletion of IGF1R downregulated RRM2, compromising RNR function and perturbing dNTP supply. The resulting delay in fork progression and hallmarks of replication stress were rescued by RRM2 overexpression, confirming RRM2 as the critical factor through which IGF1 regulates replication. Suspecting existence of a backup pathway protecting from toxic sequelae of replication stress, targeted compound screens in breast cancer cells identified synergy between IGF inhibition and ATM loss. Reciprocal screens of ATM-proficient/deficient fibroblasts identified an IGF1R inhibitor as the top hit. IGF inhibition selectively compromised growth of ATM-null cells and spheroids and caused regression of ATM-null xenografts. This synthetic-lethal effect reflected conversion of single-stranded lesions in IGF-inhibited cells into toxic DSBs upon ATM inhibition. Overall, these data implicate IGF1R in alleviating replication stress, and the reciprocal IGF:ATM codependence we identify provides an approach to exploit this effect in ATM-deficient cancers.Significance:This study identifies regulation of ribonucleotide reductase function and dNTP supply by IGFs and demonstrates that IGF axis blockade induces replication stress and reciprocal codependence on ATM.

31 March 2023
Verified
Other
Open access
TATamara Aleksic
Tamara Aleksic
NGNicki Gray
Nicki Gray
XWXiaoning Wu
Xiaoning Wu
GRGuillaume Rieunier
Guillaume Rieunier
EOEliot Osher
Eliot Osher
VMValentine M. Macaulay
Valentine M. Macaulay
Supplementary file containing: Supplementary methods Table S1: Primers, probes and siRNAs used in this study. Table S2: Demographics of men treated by radical prostatectomy for prostate cancer. Table S3: IGF-1R scores and clinical parameters in men undergoing radical prostatectomy for localized prostate cancer. Table S4: ChIP-seq: mapped reads. Figure S1: Characterization of IGF-1R expression and subcellular localization in prostate cancer. Figure S2: IGF-1R ChIP-seq in human cancer cells containing nuclear IGF-1R. Figure S3: ChIP-seq identifies IGF-1R binding peaks in promoters of JUN and FAM21 but not CCDN1 or IGF1R. Figure S4: Investigating functional consequences of coincidence of IGF-1R and RNAPol2 recruitment to JUN and FAM21A promoters. Figure S5: Depletion of JUN or FAM21A delays migration towards IGF-1 but has no effect on short-term proliferation. Figure S6: JUN expression does not correlate with total IGF-1R in prostate cancer.

31 March 2023
Verified
Other
Open access
GRGuillaume Rieunier
Guillaume Rieunier
XWXiaoning Wu
Xiaoning Wu
LHLetitia E. Harris
Letitia E. Harris
JMJack Mills
Jack Mills
ANAshwin Nandakumar
Ashwin Nandakumar
VMValentine M. Macaulay
Valentine M. Macaulay
Supplementary methods, Table S1-S2, Figure S1-S6

31 March 2023
Verified
Other
Open access
TATamara Aleksic
Tamara Aleksic
NGNicki Gray
Nicki Gray
XWXiaoning Wu
Xiaoning Wu
GRGuillaume Rieunier
Guillaume Rieunier
EOEliot Osher
Eliot Osher
VMValentine M. Macaulay
Valentine M. Macaulay
Supplementary file containing: Supplementary methods Table S1: Primers, probes and siRNAs used in this study. Table S2: Demographics of men treated by radical prostatectomy for prostate cancer. Table S3: IGF-1R scores and clinical parameters in men undergoing radical prostatectomy for localized prostate cancer. Table S4: ChIP-seq: mapped reads. Figure S1: Characterization of IGF-1R expression and subcellular localization in prostate cancer. Figure S2: IGF-1R ChIP-seq in human cancer cells containing nuclear IGF-1R. Figure S3: ChIP-seq identifies IGF-1R binding peaks in promoters of JUN and FAM21 but not CCDN1 or IGF1R. Figure S4: Investigating functional consequences of coincidence of IGF-1R and RNAPol2 recruitment to JUN and FAM21A promoters. Figure S5: Depletion of JUN or FAM21A delays migration towards IGF-1 but has no effect on short-term proliferation. Figure S6: JUN expression does not correlate with total IGF-1R in prostate cancer.